Status:
COMPLETED
Early Detection of Cardiovascular Disease
Lead Sponsor:
Dr. Amer Johri
Collaborating Sponsors:
Lantheus Medical Imaging
Conditions:
Atheroma
Cardiac Disease
Eligibility:
All Genders
18+ years
Brief Summary
The investigators plan to evaluate the correlation between carotid plaque enhancement on Contrast-enhanced ultrasound (CEUS), significant coronary artery disease (CAD), and cardiovascular (CV) outcome...
Detailed Description
Study Design: The investigators will conduct a prospective, single-center, observational study at the Cardiovascular Imaging Network at Queen's (CINQ, www.CINQLab.com). This facility allows a CEUS pro...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- \>18 years of age
- Outpatients referred for clinically indicated angiography for assessment of CAD
- Low - Intermediate Framingham risk (\<20%)
- Absence of clinical contraindication to angiography
- Able and willing to give informed consent
- Exclusion criteria:
- Patients presenting with acute coronary syndrome
- Patients with previously known significant CAD (any lesion \>50%) or percutaneous coronary intervention or coronary artery bypass surgery
- Previous carotid surgery or angioplasty
- Documented allergy to echo contrast
Exclusion
Key Trial Info
Start Date :
December 6 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 11 2022
Estimated Enrollment :
610 Patients enrolled
Trial Details
Trial ID
NCT03466255
Start Date
December 6 2016
End Date
January 11 2022
Last Update
June 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen's University, Cardiovascular Imaging Network at Queen's (CINQ), Kingston General Hospital
Kingston, Ontario, Canada, K7L 3N6